We've found
17,819
archived clinical trials in
Brain Cancer
We've found
17,819
archived clinical trials in
Brain Cancer
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Surgery in Treating Children With Neuroblastoma
Updated: 2/29/2016
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Updated: 3/1/2016
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Click here to add this to my saved trials

Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Updated: 3/2/2016
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Status: Enrolling
Updated: 3/2/2016
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Updated: 3/2/2016
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials

Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Updated: 3/2/2016
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Status: Enrolling
Updated: 3/2/2016
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Updated: 3/2/2016
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials

Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
Updated: 3/2/2016
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Status: Enrolling
Updated: 3/2/2016
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
Updated: 3/2/2016
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials

Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
Updated: 3/2/2016
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Status: Enrolling
Updated: 3/2/2016
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
Updated: 3/2/2016
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Status: Enrolling
Updated: 3/2/2016
Click here to add this to my saved trials

A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
Click here to add this to my saved trials

A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
Click here to add this to my saved trials

A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
Click here to add this to my saved trials

A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
Click here to add this to my saved trials

A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
Click here to add this to my saved trials

A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
Click here to add this to my saved trials

A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
Click here to add this to my saved trials

A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
Click here to add this to my saved trials

A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
A Study of IMC-A12 in Islet Cell Cancer
Updated: 3/3/2016
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Updated: 3/4/2016
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Click here to add this to my saved trials
